Cisatracurium is the safest muscle relaxant for dialysis patients with kidney failure
For patients with end-stage renal disease on dialysis, cisatracurium is the preferred muscle relaxant due to its organ-independent elimination that is unaffected by renal failure. 1
Why Cisatracurium is Superior
Cisatracurium undergoes predominantly non-enzymatic elimination (Hofmann degradation), meaning it does not rely on kidney or liver function for clearance. This results in:
- Identical pharmacokinetics and pharmacodynamics in patients with and without renal failure 1
- No accumulation with repeated dosing or prolonged infusions 1
- Lower laudanosine production compared to atracurium (because cisatracurium is more potent, requiring smaller doses) 1
Second Choice: Atracurium
If cisatracurium is unavailable, atracurium is the next best option. Approximately 50% undergoes organ-independent elimination (Hofmann reaction and ester hydrolysis), with similar pharmacokinetics in renal failure patients 1. While its metabolite laudanosine does accumulate in renal failure, it does not reach toxic concentrations even after 72-hour infusions 1. Research confirms atracurium shows no difference in duration of action or recovery between dialysis and normal patients 2, and it required reversal less frequently than vecuronium in kidney transplant patients 3.
Avoid These Agents
Rocuronium and vecuronium are eliminated primarily via kidney and bile, resulting in:
- Reduced clearance in renal failure 1
- Prolonged duration of action with repeated doses in dialysis patients 2
- Greater need for reversal agents 3
Baclofen (oral muscle relaxant for spasticity) is absolutely contraindicated in dialysis patients. Even two 10mg doses can cause profound neurotoxicity and requires emergency dialysis for removal 4. Over 80% is renally excreted, making ESRD patients extremely vulnerable to toxicity 4, 5.
Dosing Considerations
- Use standard initial doses for all muscle relaxants in renal failure patients—do not reduce the induction dose 1
- The onset time remains unchanged despite renal failure 1
- Monitor neuromuscular function carefully, as duration of action may be prolonged with agents other than cisatracurium/atracurium
Reversal Agent
Sugammadex can be used at usual doses in renal failure patients despite renal elimination 1. However, the predictable offset of cisatracurium minimizes the need for reversal agents in the first place.